Kyn Therapeutics has two new executives on its management team. Jeffrey Ecsedy, the Boston company’s senior vice president, R&D, was promoted to chief scientific officer. Also, Jason Sager is now chief medical officer after holding that post on an interim basis for the past two years. Kyn emerged in 2017 with $49 million in funding to develop cancer drugs that target the metabolism of both cancer and immune cells.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
